Study May Lead to Discovery of New RCC Biomarkers

Share this content:

the Cancer Therapy Advisor take:

In a small study of five patients with renal cell carcinoma (RCC), researchers found expression patterns of long non-coding RNAs (lncRNAs) and aberrant lncRNAs and mRNAs in tumor samples versus non-tumor tissues. A microarray of lncRNA identified 27,279 lncRNAs in samples of RCC—480 of which were significantly upregulated and 417 of which were significantly downregulated, as compared with non-tumor tissue. Researchers also discovered 19,995 mRNAs—458 of which were significantly upregulated and 413 of which were significantly downregulated. They also noted a link between AK096725 and ENST00000453068 in 70 paired samples. This connection between RCC and AK096725 in particular may lead to the discovery of new biomarkers in RCC, according to the researchers. 

Could Dendritic Cell Immunotherapy Transform Kidney Cancer Treatment?
Study May Lead to Discovery of New RCC Biomarkers
Recent large-scale transcriptome analyses have found large numbers of transcripts, including that of long non-coding RNAs (lncRNAs), which are aberrant in various diseases, especially cancers. However, it is not clear whether lncRNAs are involved specifically in renal cell carcinoma (RCC)...
READ FULL ARTICLE From PLOS ONE

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs